Feasibility and Safety of Collecting Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy
Phase 1
20
about 2.8 years
18–85
1 site in CA
About this study
Researchers are testing the safety and feasibility of collecting autologous hematopoietic stem cells to be combined with CAR T-cell therapy for people with relapsed/refractory hematological diseases. The trial will evaluate how well the target dose of HSCs can be collected from at least 50% of enrolled patients, as well as assess the safety of this combination treatment based on cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in the first 60 days post CAR T dosing, along with adverse events and serious adverse events. It will follow an open-label, single-center design.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive autologous hematopoietic stem cells added to planned CAR T
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cell therapy
Secondary: Assess safety and tolerability of combining aHSCs with an FDA-approved CAR T regimen within first 52 weeks of aHSC infusion., Median overall survival (OS) for the duration of the study, Median progression-free survival (PFS) for the duration of the study, Response rate of CAR T at 6 weeks.
Oncology